IgE autoantibodies in serum and skin of non-bullous and bullous pemphigoid patients.
Journal
Journal of the European Academy of Dermatology and Venereology : JEADV
ISSN: 1468-3083
Titre abrégé: J Eur Acad Dermatol Venereol
Pays: England
ID NLM: 9216037
Informations de publication
Date de publication:
Apr 2021
Apr 2021
Historique:
received:
11
05
2020
revised:
28
09
2020
accepted:
02
10
2020
pubmed:
16
10
2020
medline:
15
5
2021
entrez:
15
10
2020
Statut:
ppublish
Résumé
Non-bullous pemphigoid (NBP) is a pemphigoid variant which frequently resembles other pruritic skin diseases. In contrast with bullous pemphigoid (BP), blisters are absent. In BP, previous studies showed that IgE autoantibodies may be involved in its pathogenesis. IgE-activated mast cells, basophils and eosinophils may participate in BP by inducing pruritus and possibly blister formation, although the differential role of IgE in NBP compared with BP has not yet been described. To assess IgE in serum and skin of NBP and BP patients. We examined total IgE and pemphigoid-specific IgE in the serum of 68 NBP and 50 BP patients by enzyme-linked immunosorbent assay (ELISA). Sera of 25 pemphigus patients and 25 elderly patients with pruritus were included as controls. Skin biopsies of 14 NBP and 14 BP patients with the highest IgE titres to NC16A were stained for IgE by immunofluorescence techniques. Total IgE was elevated in 63% of NBP and 60% of BP patients, and in 20% of pemphigus controls, as well as 60% of elderly controls. IgE ELISAs were more frequently positive in BP than in NBP (NC16A 18% vs. 9%, P = 0.139; BP230 34% vs. 22%, P = 0.149). IgE ELISAs for NC16A and BP230 were positive in 8% and 20% of elderly controls, respectively, while all pemphigus controls were negative. Two of 28 biopsies (7%; one NBP, one BP) showed linear IgE along the basement membrane zone, while in most biopsies (71% NBP; 86% BP) IgE was bound to dermal cells. Since IgE was present in the serum and skin of both NBP and BP patients, this supports IgE-dependent mechanisms common to both diseases, such as pruritus. However, it remains to be elucidated whether IgE contributes to blister formation in BP.
Sections du résumé
BACKGROUND
BACKGROUND
Non-bullous pemphigoid (NBP) is a pemphigoid variant which frequently resembles other pruritic skin diseases. In contrast with bullous pemphigoid (BP), blisters are absent. In BP, previous studies showed that IgE autoantibodies may be involved in its pathogenesis. IgE-activated mast cells, basophils and eosinophils may participate in BP by inducing pruritus and possibly blister formation, although the differential role of IgE in NBP compared with BP has not yet been described.
OBJECTIVE
OBJECTIVE
To assess IgE in serum and skin of NBP and BP patients.
METHODS
METHODS
We examined total IgE and pemphigoid-specific IgE in the serum of 68 NBP and 50 BP patients by enzyme-linked immunosorbent assay (ELISA). Sera of 25 pemphigus patients and 25 elderly patients with pruritus were included as controls. Skin biopsies of 14 NBP and 14 BP patients with the highest IgE titres to NC16A were stained for IgE by immunofluorescence techniques.
RESULTS
RESULTS
Total IgE was elevated in 63% of NBP and 60% of BP patients, and in 20% of pemphigus controls, as well as 60% of elderly controls. IgE ELISAs were more frequently positive in BP than in NBP (NC16A 18% vs. 9%, P = 0.139; BP230 34% vs. 22%, P = 0.149). IgE ELISAs for NC16A and BP230 were positive in 8% and 20% of elderly controls, respectively, while all pemphigus controls were negative. Two of 28 biopsies (7%; one NBP, one BP) showed linear IgE along the basement membrane zone, while in most biopsies (71% NBP; 86% BP) IgE was bound to dermal cells.
CONCLUSION
CONCLUSIONS
Since IgE was present in the serum and skin of both NBP and BP patients, this supports IgE-dependent mechanisms common to both diseases, such as pruritus. However, it remains to be elucidated whether IgE contributes to blister formation in BP.
Identifiants
pubmed: 33058320
doi: 10.1111/jdv.16996
pmc: PMC7983951
doi:
Substances chimiques
Autoantibodies
0
Autoantigens
0
Non-Fibrillar Collagens
0
Immunoglobulin E
37341-29-0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
973-980Informations de copyright
© 2020 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd on behalf of European Academy of Dermatology and Venereology.
Références
Br J Dermatol. 2017 Dec;177(6):1644-1653
pubmed: 28868796
Exp Dermatol. 2016 Jan;25(1):50-5
pubmed: 26475989
Clin Exp Immunol. 1974 Oct;18(2):193-200
pubmed: 4619597
Br J Dermatol. 2017 Jul;177(1):141-151
pubmed: 27716903
J Dermatol. 2017 Feb;44(2):189-193
pubmed: 28497856
J Invest Dermatol. 2016 Dec;136(12):2495-2498
pubmed: 27456755
Acta Derm Venereol. 2017 Apr 6;97(4):464-471
pubmed: 27868136
J Dermatol Sci. 2008 Feb;49(2):153-61
pubmed: 17920818
J Am Acad Dermatol. 2018 May;78(5):989-995.e2
pubmed: 29102490
JAMA Dermatol. 2017 Jan 1;153(1):30-38
pubmed: 27829102
Br J Dermatol. 2011 Nov;165(5):1133-7
pubmed: 21711326
J Invest Dermatol. 2003 May;120(5):784-8
pubmed: 12713582
Br J Dermatol. 2003 Oct;149(4):910-2
pubmed: 14616403
Am J Clin Dermatol. 2019 Apr;20(2):209-216
pubmed: 30421306
J Immunol Methods. 2009 Jul 31;346(1-2):18-25
pubmed: 19422829
J Immunol. 1996 Oct 15;157(8):3642-7
pubmed: 8871665
Arch Dermatol. 2008 Jan;144(1):41-8
pubmed: 18209167
J Biol Chem. 2011 Apr 29;286(17):15003-9
pubmed: 21393236
J Clin Invest. 1994 May;93(5):2022-30
pubmed: 8182134
J Eur Acad Dermatol Venereol. 2020 Jan;34(1):161-165
pubmed: 31423677
Br J Dermatol. 2014 Apr;170(4):943-7
pubmed: 24734947
Br J Dermatol. 2009 Feb;160(2):429-32
pubmed: 18808416
J Am Acad Dermatol. 2019 Aug;81(2):355-363
pubmed: 31009674
Br J Dermatol. 2020 May;182(5):1221-1227
pubmed: 31330562
J Immunol. 2011 Jul 1;187(1):553-60
pubmed: 21646296
Int Immunopharmacol. 2007 Dec 20;7(14):1909-23
pubmed: 18039528
Front Med (Lausanne). 2018 Jul 10;5:201
pubmed: 30042946
Br J Dermatol. 1998 Jan;138(1):71-6
pubmed: 9536225
Clin Dermatol. 2012 Jan-Feb;30(1):3-16
pubmed: 22137222
Allergy. 2017 Jul;72(7):1105-1113
pubmed: 28135772
Front Immunol. 2018 Apr 17;9:779
pubmed: 29719538
J Invest Dermatol. 2009 Apr;129(4):919-26
pubmed: 19177144
J Allergy Clin Immunol. 2009 Mar;123(3):704-5
pubmed: 19152970
Lancet. 2013 Jan 26;381(9863):320-32
pubmed: 23237497
J Am Acad Dermatol. 2000 Apr;42(4):577-83
pubmed: 10727301
Arch Dermatol. 1992 Jun;128(6):791-4
pubmed: 1376103
J Dermatol Sci. 2015 Apr;78(1):21-5
pubmed: 25724363
Exp Dermatol. 2017 Dec;26(12):1154-1162
pubmed: 28887824
Sci Rep. 2016 Nov 15;6:37125
pubmed: 27845416
Nat Rev Immunol. 2008 Mar;8(3):205-17
pubmed: 18301424
Annu Rev Immunol. 2008;26:705-39
pubmed: 18370925
Clin Dermatol. 2013 Jul-Aug;31(4):391-399
pubmed: 23806156
JAMA Dermatol. 2019 Feb 1;155(2):158-165
pubmed: 30624575
J Invest Dermatol. 2001 Nov;117(5):1091-6
pubmed: 11710917
Annu Rev Pathol. 2016 May 23;11:175-97
pubmed: 26907530
J Clin Immunol. 1998 May;18(3):202-9
pubmed: 9624579
J Immunol. 2014 Nov 1;193(9):4415-28
pubmed: 25261486
Br J Dermatol. 2015 Nov;173(5):1274-6
pubmed: 25912001
Arch Dermatol Res. 2015 Nov;307(9):849-54
pubmed: 26404084
Br J Dermatol. 2019 May;180(5):1107-1113
pubmed: 30311191
Br J Dermatol. 2009 Aug;161(2):306-12
pubmed: 19485996
J Invest Dermatol. 2018 May;138(5):1032-1043
pubmed: 29246800
Arch Dermatol Res. 2018 Apr;310(3):255-259
pubmed: 29423547
Arch Dermatol Res. 2018 Jan;310(1):11-28
pubmed: 29071428
J Invest Dermatol. 2005 Sep;125(3):467-72
pubmed: 16117787
Exp Gerontol. 2018 May;105:4-9
pubmed: 29111233
Arch Dermatol. 1974 Sep;110(3):378-81
pubmed: 4217592
J Clin Invest. 2006 Nov;116(11):2892-900
pubmed: 17024247
Br J Dermatol. 2017 Feb;176(2):517-519
pubmed: 27344014